Living with hemolytic anemia can feel like running a race with a weight vest on. The condition causes red blood cells to be destroyed faster than the body can replace them, leading to persistent fatigue, weakness, and shortness of breath. Simple activities like climbing stairs or carrying groceries can become exhausting. For some, the skin may turn pale or yellow (jaundice), adding visible distress to the physical symptoms. While the diagnosis can be unsettling, the condition is often manageable with the right medical approach.

Treatment is essential to stop the premature destruction of red blood cells and restore oxygen levels in the body. Without intervention, severe anemia can strain the heart and damage other organs. Because hemolytic anemia stems from various causes, ranging from autoimmune disorders and infections to reactions to certain medicines, treatment is highly specific. Doctors tailor the plan based on whether the hemolysis is inherited or acquired and how quickly the red blood cells are breaking down (National Heart, Lung, and Blood Institute, 2022).

Overview of treatment options for Hemolytic Anemia

The primary goal of treating hemolytic anemia is to halt the destruction of red blood cells and treat the underlying cause. If the condition is triggered by a specific medication or infection, removing the trigger or treating the infection may be sufficient. However, for autoimmune hemolytic anemia (AIHA), where the immune system attacks the body’s own cells, suppressing the immune response is the central strategy.

Treatment generally involves a combination of pharmacological therapies to calm the immune system and supportive measures to help the body produce new blood cells. In severe or emergency cases, blood transfusions may be necessary to stabilize the patient quickly. For chronic cases that do not respond to medication, surgical removal of the spleen (splenectomy) is sometimes considered, as the spleen is a primary site where blood cells are destroyed.

Medications used for Hemolytic Anemia

For autoimmune hemolytic anemia, corticosteroids are the standard first-line treatment. Drugs such as prednisone are prescribed to rapidly suppress the immune system’s attack on red blood cells. Clinical experience suggests that corticosteroids effectively stop hemolysis in a majority of patients within a few weeks.

If corticosteroids are ineffective, cause too many side effects, or if the disease returns when the dose is lowered, doctors often prescribe stronger immunosuppressive agents or “steroid-sparing” drugs. Rituximab is a widely used monoclonal antibody in this setting. Other agents may include azathioprine, cyclophosphamide, or cyclosporine.

For specific types of hemolytic anemia involving the complement system (a part of the immune system), specialized inhibitors like eculizumab may be used. Additionally, nearly all patients are prescribed folic acid supplements. While not a cure, folic acid provides the essential raw materials the bone marrow needs to keep up with the high demand for new red blood cell production (Mayo Clinic, 2023).

How these medications work

Corticosteroids work by broadly dampening the immune system’s activity. They reduce the production of the antibodies that are tagging the red blood cells for destruction and interfere with the macrophages (scavenger cells) that eat them.

Rituximab works more specifically by targeting B-cells, the white blood cells responsible for making the antibodies that attack the red blood cells. By depleting these B-cells, the production of harmful antibodies drops, allowing the red blood cells to survive longer.

Immunosuppressants like azathioprine work by inhibiting the division of white blood cells, generally lowering the immune system’s aggressiveness. Folic acid acts as a nutritional fuel; since the bone marrow is working overtime to replace destroyed cells, it depletes nutrient stores quickly. Supplementation ensures the “factory” doesn’t run out of supplies.

Side effects and safety considerations

Corticosteroids, though effective, pose risks with long-term use, including weight gain, fluid retention, high blood pressure, mood swings, diabetes, and osteoporosis. Doctors aim to quickly reduce the dose to the lowest effective level.

Immunosuppressive drugs and rituximab increase infection risk by lowering immunity. Patients must monitor for fever or illness signs. Some treatments require pre-screening for conditions like hepatitis or tuberculosis. Seek immediate medical care for severe fatigue, dark urine, or chest pain (Johns Hopkins Medicine, 2024).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  2. Mayo Clinic. https://www.mayoclinic.org
  3. Johns Hopkins Medicine. https://www.hopkinsmedicine.org
  4. American Society of Hematology. https://www.hematology.org

Medications for Hemolytic Anemia

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemolytic Anemia.

Found 21 Approved Drugs for Hemolytic Anemia

Eculizumab

Brand Names
Soliris, BKEMV, Epysqli

Eculizumab

Brand Names
Soliris, BKEMV, Epysqli
EPYSQLI is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection, USP, is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Ferriprox

Generic Name
Deferiprone

Ferriprox

Generic Name
Deferiprone
FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes.

Deferasirox

Brand Names
Deferasorox, Jadenu, Exjade

Deferasirox

Brand Names
Deferasorox, Jadenu, Exjade
Deferasirox granule is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.

Ultomiris

Generic Name
Ravulizumab

Ultomiris

Generic Name
Ravulizumab
ULTOMIRIS is indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) ( 1 ). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
Showing 1-5 of 21
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances